

Review

Luigi Della Corte¹ / Marco Noventa² / Michal Ciebiera³ / Maria Magliarditi⁴ / Zaki Sleiman⁵ / Erbil Karaman⁶ / Ursula Catena⁷ / Calogero Salvaggio⁸ / Giovanni Falzone⁹ / Simone Garzon¹⁰

Phytotherapy in endometriosis: an up-to-date review

¹ Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy, E-mail: dellacorte.luigi25@gmail.com

² Department of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, Padua, Italy, E-mail: marco.noventa@gmail.com

³ Second Department of Obstetrics and Gynecology, The Center of Postgraduate Medical Education, Warsaw, Poland, E-mail: michal.ciebiera@gmail.com

⁴ Department of Obstetrics & Gynaecology, Policlinico Universitario Gazzi, University of Messina, Messina, Italy, E-mail: mariamagliarditi@hotmail.com

⁵ Department of Obstetrics and Gynecology, Lebanese American University, Beirut, Lebanon, E-mail: zakinexus@hotmail.com

⁶ Department of Obstetrics and Gynecology, Yuzuncu Yil University Medical Faculty, Van, Turkey, E-mail: erbil84@gmail.com

⁷ Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, E-mail: ursula.catena@gmail.com. <https://orcid.org/0000-0002-7813-7993>.

⁸ Azienda Sanitaria Provinciale 2 Caltanissetta, "Sant'Elia" Hospital, Caltanissetta, Italy, E-mail: lillosalvaggio@libero.it

⁹ Obstetrics and Gynaecology Unit, "Umberto I" Hospital, Enna, Italy, E-mail: gio.falzone@alice.it

¹⁰ Department of Obstetrics and Gynecology, "Filippo Del Ponte" Hospital, University of Insubria, Varese, Italy, E-mail: simone.garzon@yahoo.it. <https://orcid.org/0000-0002-5840-699X>.

Abstract:

Endometriosis is a benign gynecological disease which symptoms can provide a severe impact on patient's quality of life with subsequent impact on psychological well-being. Different therapeutic strategies are available to treat this disease, such as surgery, hormonal therapies, and nonsteroidal anti-inflammatory drugs. Nevertheless, the efficacy of conventional medical treatments is limited or intermittent in most of the patients due to the associated side effects. Therefore, a woman with endometriosis often search for additional and alternative options, and phytotherapy might be a promising alternative and complementary strategy. Different medicinal plants, multicomponent herbal preparations, and phytochemicals were investigated for pharmacological proprieties in endometriosis therapy. In most of the cases, the effect on endometriosis was related to phenolic compounds, such as flavonoids and phenolic acids reporting anti-inflammatory, proapoptotic, antioxidant, and immunomodulatory functions. Moreover, some phytochemicals have been related to a strong phytoestrogenic effect modulating the estrogen activity. Although promising, available evidence is based on in vitro and animal models of endometriosis with a limited number of well-performed clinical studies. There are almost none randomized control trials in this area. Therefore, properly constructed clinical trials are mandatory to achieve more conclusive results about the promising role of phytotherapy in the management of endometriosis.

Keywords: endometriosis, flavonoids, pharmacological treatments, phytochemicals, phytotherapy

DOI: 10.1515/jcim-2019-0084

Received: March 26, 2019; **Accepted:** July 28, 2019

Endometriosis: An overview

Endometriosis is a benign gynecological disease that affects 5–10% of women in fertile age [1]. It is a chronic inflammatory estrogen-dependent pathology that consists in the presence of endometrial-like tissue, with stroma and glands, outside the uterus, involving peritoneum, adnexa, bowel, and other organs, in and outside the abdominal cavity, with superficial or deep infiltrating implants [2–4]. This ectopic endometrial-like tissue induces a chronic inflammatory response and damage–repair mechanisms with subsequent scar tissue formation and adhesions that are able to distort woman's pelvic anatomy [5–7]. Although it can be asymptomatic, in the majority of the cases it is related to dysmenorrhea, chronic pelvic pain, dyspareunia, abnormal uterine bleeding, and

Luigi Della Corte is the corresponding author.

© 2019 Walter de Gruyter GmbH, Berlin/Boston.

infertility [2, 8–10]. Symptoms, particularly pain, correlate poorly with the extension and grade of endometriosis, and the physiology of nociception and pain characteristics are not completely understood [10, 11]. Nevertheless, all these symptoms are able to provide a severe impact on patient's quality of life with a subsequent impact on psychological well-being [3, 12–17].

The full diagnosis of endometriosis requires surgical inspection, preferably with histological confirmation in collected specimen [18–20].

Furthermore, several studies have suggested an association between endometriosis and development of ovarian cancer with the predominant subtypes of epithelial ovarian cancer [21–24] while it is not fully understood if endometriosis may be also associated with endometrial and breast cancer [25–27].

Surgery represents a key treatment for the disease and aims to remove ectopic lesions and reestablish the normal anatomy, reporting reduced pelvic pain and improving reproductive outcomes [28–32]. Nevertheless, surgical treatment can be avoided when medical therapies achieve symptoms under control and counteract the disease development via pharmacological inhibition of ovulation and menstruation, although drugs do not cure the disease because lesions are not eradicated [33]. In these cases, medical therapy represents one of the most appropriate approaches based on the benefits versus the risks for the patients and the tolerability profile [34, 35]. This approach may allow avoiding repeated surgery for relapsing disease in young patients, allowing to plan the best moment to perform surgery during the reproductive age, if required [36]. Indeed, surgery is generally effective in pain relief, but its benefit is often temporary for the risk of relapsing disease, and due to this risk, medical therapies have a further key role in the management of patients in the postoperative period [11, 18, 37].

In the last few years, the advances in neuroendocrinology, endocrinology, tumorigenesis, neurogenesis, and genomics are transforming the current management approaches for endometriosis. In this regard, GnRH antagonists, SPRM/SERM, aromatase inhibitors, immunomodulators, and antiangiogenic drugs appear as emerging and promising medical treatments for endometriosis. Further studies are needed in order to promote personalized medicine for patients with endometriosis [38–40].

Pharmacological treatment for endometriosis

Usually, the medical therapy consists in different hormonal drugs, including combined hormonal contraceptives, progestogens, anti-progestogens, levonorgestrel-releasing intrauterine system, gonadotropin releasing hormone analogs with or without add-back therapies; and to date, there is no robust evidence to support a specific hormonal therapy over the others [3, 18]. Additionally, endometriosis requires the management of pain symptoms, and nonsteroidal anti-inflammatory drugs represent often the first line [41].

Although multiple pharmacological strategies are available, a recent systematic review showed that the efficacy of conventional medical treatments is limited or intermittent in most patients. Only in 29 out of 58 articles, involving 125 treatment arms, the response of pain symptoms to treatment was reported. About 5–59% of the women reported reduced or unchanged persistent pain, 11–19% of the women had experienced no reduction in pain at the end of the treatment, and 17–34% reported a recurrence of symptoms after treatment cessation [42]. Additionally, adverse effects and the impairment of the reproductive function of the pituitary–gonadal axis represent a cause of further concerns, that with the often-incomplete resolutions of symptoms are a cause of dissatisfaction with conventional treatments. About 5–16% of enrolled subjects discontinued the therapy due to adverse events or lack of efficacy [42–44]. On that basis, the woman with endometriosis often searches for additional and alternative options to improve their symptoms and psychological well-being like other gynecological diseases, such as fibroids [45]. A recent study reported that up to 76% of the total women affected by endometriosis use self-management strategies [46]. These complementary strategies include different options such as the application of heat, relaxation techniques and yoga, movement and stretching, rest, physiotherapy, psychotherapy, acupoint, diet changes and supplementations, and phytotherapy. These women reported that many of these natural treatments are effective in the management of endometriosis, although none of these strategies are entirely curative and neither can eradicate the endometriotic lesions, and the lack of safety and efficacy studies represent a limit to their uses [47–49]. Nevertheless, because conventional therapies are not completely effective in all women, individual treatment options should be discussed and initiated by clinicians to provide the best comprehensive treatment, and natural therapies represent a source of paramount importance that can contribute to the healing process and to the control of severe symptoms as they emphasize the general health and well-being [49].

Phytotherapy

Phytotherapy, with the use of medicinal plants, is a possible source of new strategies to manage the disease, as it was demonstrated in other gynecological disorders [48, 50, 51]. In this regard, literature about the topic confirms the positive effects of phytotherapy in the treatment of menopausal symptoms or sexual dysfunctions [52–54].

Different plants offer a variety of therapeutic properties and may be important sources of minerals, vitamin, and phytohormones.

Moreover, different pathways involved in the etiopathogenesis of endometriosis [55] can be a target of herbal medicines, supporting with molecular mechanism a possible effect [48, 56]. The decreased apoptosis and the improved cell survival are often reported in eutopic and ectopic endometrium of affected woman as compared to healthy controls, and some studies investigated the effect of different plants on apoptosis and cell survival [57–60]. Similarly, other pathways having a key role in the development of endometriosis were investigated as possible target of phytotherapy [56], such as angiogenesis mediated by vascular endothelial growth factor (VEGF) [49, 61], the altered inflammatory microenvironment involving cytokines and immune cells [62–64], the oxidative stress [65, 66], and the attachment and invasion mechanisms [67–69]. Moreover, there is evidence that specific herbs may have an impact on the epigenome, representing a therapeutic strategy to potentially reverse the aberrant epigenetic changes reported in endometriosis [70, 71]. On this basis, different plants were investigated as a complex group of molecular compounds effective in endometriosis [56].

Alchemilla

The genus *Alchemilla* (Rosaceae) including almost 100 species is used in phytotherapy to treat various gynecological and non-gynecological diseases, such as aphthous stomatitis [72]. These plants have a high content of phenolic compounds (flavonoids and tannins) that induce regeneration of skin epithelium and have anti-inflammatory and antiangiogenesis activities, that may explain the reported wound-healing proprieties and the reduced endometriosis formation in rat models [73–75].

Allium sativum

Allium sativum (garlic) has different pharmacological properties, such as the reduction of cardiovascular diseases risk, and the antitumor, antimicrobial, and antianxiety effects [76, 77]. It was associated with proapoptotic and anti-angiogenetic functions inducing caspase and downregulating VEGF [78, 79]. Some molecular derivatives of garlic were reported able to modulate inflammatory response suppressing leukocyte production of pro-inflammatory cytokines and improving the expression of interleukine-10 (IL-10). Moreover, they were reported able to reduce the oxidative stress improving antioxidant enzymes [80–83]. In endometriosis, it was reported able to reduce cell proliferation, attenuating the expression of VACM-1, ICAM-1, and other proteins involved in the migration and metastasis [76, 84].

Salvia miltiorrhiza

Salvia miltiorrhiza (danshen in Chinese) represents one of the most used plants in Chinese traditional medicine. Extracts from the root reported pharmacological activities such as antiviral, antioxidant, antimicrobial, anti-inflammatory, anticancer, and cardiovascular effects [85–87]. About anticancer effects, *S. miltiorrhiza* may prevent cancer initiation through antioxidation proprieties and may inhibit cells proliferation inducing apoptosis or autophagy [88]. *S. miltiorrhiza* extract reported antiproliferative, proapoptotic, and anti-angiogenetic functions, modulating caspases, proapoptotic proteins, and VEGF signaling [89–92]. Further studies reported the ability to modulate the expression of metalloproteases and adhesion molecules, such as ICAM-1 and VCAM-1, repressing invasion and growth of human cancer cells [93, 94]. These effects involve many pathways that may play a key role even in the endometriosis treatment. In endometriosis, extracts of this plant reduced the levels of cancer antigen 125 (CA-125) and of pro-inflammatory cytokines in the peritoneal fluids of rat models [95–97].

Artemisia princeps

Artemisia princeps (family Asteraceae) was associated with antitumor, antipyretic, antimalarial, antihemorrhagic, antioxidant, and antiviral properties. A decreased expression levels of ICAM-1 and VCAM-1 and a reduction of pro-inflammatory cytokines such as interferon- γ , IL-2, tumor necrosis factor- α (TNF- α), and IL-1 β were reported [98–100], consistently with the reduced cell proliferation of inflammatory T leukocytes [101]. Leaf extract has a proapoptotic effect on endometriotic epithelial cells suppressing expressions of antiapoptotic factors such as Bcl-2 and activating caspase in a dose-dependent manner [102].

Aloe vera

Aloe vera (genus *Aloe*, family Xanthorrhoeaceae) is a well-known topical and oral therapeutic agent for the beauty, medicinal, and skin care properties. This plant is used in phytotherapy for the gastrointestinal activities, the hepatoprotective properties, and the effects in skin problems, such as wounds, injuries, and infective diseases [103]. The mannose 6-phosphate present in Aloe gel is proposed as the active agent improving wound healing by increasing cell phagocytic activity, fibroblasts proliferation, and hyaluronic acid and collagen synthesis [104]. Moreover, *A. vera* was associated to a strong immunomodulatory activity with anti-inflammatory effects [105], to antioxidant properties [106] and to an anticancer activity modulating neo-angiogenesis, cell proliferation, and apoptosis [104]. On that basis, *A. vera* was tested in rat models of endometriosis, resulting in an inhibited formation and regression of endometriotic lesions and in a reduction of oxidative stress markers with a raise of antioxidant levels in the peritoneal fluid [107].

Viburnum opulus

The genus *Viburnum* (family Caprifoliaceae) comprises more than 230 species. Its fruits are widely used for the medical properties in different diseases, comprising heart disease, coughs, digestive troubles, and bleeding. Moreover, it was reported effective in gynecological disorders, such as primary and secondary dysmenorrhea and ovarian cysts [108]. In the endometriosis rat model, *Viburnum opulus* was reported associated with a reduction of endometriotic implants volume and to the remission of TNF- α , VEGF, and IL-6 levels [109].

Multicomponent herbal preparations

Different studies investigated multicomponent herbal preparations, demonstrating an efficacy via anti-inflammatory, antiproliferative, and proapoptotic mechanisms. First, a mixture of *Hippophae rhamnoides* L. and *Hypericum perforatum* L. oils demonstrated an anti-inflammatory and antiangiogenesis activities with an anti-endometriosis effect, reporting a significant volume reduction of endometriotic implants [48, 110]. Then, a mixture of *Curcuma zedoaria* and *S. miltiorrhiza* was applied in a clinical study to treat endometriosis compared with danazol. Study results were comparable, and the mixture was reported as effective and safe as medicine [111]. A rat model was used to test the Fubao Danggui Jiao that is a Chinese Materia Medica variant. The study reported a significantly reduced volume of the surviving endometriotic implants as compared with danazol [112]. Further different decoctions, traditionally used to treat endometriosis in China, were reported effective in the management of endometriosis, including Xuefu Zhuyu, Xiaochaihu, Qu Yi Kang, Yi Wei Ning, Yi Wei San, and Huoxue Xiaoyi [44]. Xuefu Zhuyu was reported effective in more than the 90% of cases in relieve dysmenorrhea similarly to mifepristone, and it was reported able to induce the shrink of ectopic lesions and promote fertility [48]. Xiaochaihu was reported able to reduce the expression of aromatase protein and COX-2 protein in endometriotic tissues [113]. Qu Yi Kang was related to the reduction of IL-2 and IL-6 levels in peritoneal fluid, to the inhibition of endometriotic tissue growth and proliferation, and to the reduction of estrogen receptor (ER) and VEGF protein expression within the endometriotic tissue in rat models [48].

There are numerous plants and multicomponent herbal preparations investigated for the medical management of endometriosis other than those reported, and a growing body of evidence, reporting promising results, suggests a potential key role of them in the treatment of endometriosis [56]. Nevertheless, although available evidence suggests a utility of phytotherapy in endometriosis and provides the molecular mechanism explaining the results, the majority of studies had been performed in cellular and animal models of endometriosis with a limited number of clinical studies. Therefore, it should be remembered that not enough data are available for the clinical recommendations of these plants and preparations, and further studies are required before their implementation in the management of endometriosis.

Specific phytochemicals

Behind the use of plants, some specific phytochemicals extracted from plants were investigated as a single agent with pharmacological proprieties in endometriosis, such as curcumin, genistein, and resveratrol.

Curcumin

Curcumin is the major chemical compound of *Curcuma longa* (Zingiberaceae) [114]. Research suggests that curcumin can help in the management of oxidative and inflammatory conditions, metabolic syndrome, arthritis, anxiety, and hyperlipidemia. Many pharmacological activities have been attributed to these compounds such as antioxidant, antiproliferative, anti-inflammatory, anticarcinogenic, and antibacterial activities [115, 116]. Curcumin was related to a reduction of estrogen level and stoma cells number in endometriotic implants [117]. It was reported able to induce apoptosis modulating pro- and antiapoptotic proteins, to inhibit angiogenesis via inhibition of VEGF signaling pathways, to modulate inflammatory response acting on the secretion of inflammatory mediators such as TNF- α and TGF- β 1, and to reduce oxidative stress. It also suppressed invasiveness via decreasing metalloproteases and modulating E-cadherin pathway [118–124]. These results suggest that it may help in the management of endometriosis as a dietary and pharmacological agent, but further research is necessary [125].

Genistein

Genistein is an isoflavone with strong phytoestrogenic effects, which is isolated from soy. A growing body of evidence, from in vitro and in vivo studies, reported a remarkable chemopreventive activity mediated by modulating the transduction of many genes involved in cell-cycle regulation, cell–cell and cell–matrix adhesion, invasion, apoptosis, and angiogenesis [126, 127].

This chemopreventive activity is consistent with the observed reduction of endometriotic implants dimension, that was explained by its antiproliferative and antiangiogenesis activity as well as the inhibition of enzymes involved in the steroid metabolism [128]. Genistein reported proapoptotic and anti-angiogenic functions explained by the modulation of different pathways involved in the apoptosis and downregulating VEGF [129, 130]. Additional studies demonstrate anti-inflammatory function and antioxidant activity, modulating cytokines and increasing antioxidant enzymes activities [131, 132]. Moreover, consistently with those reported in a study investigating the role of genistein as treatment and preventive agent in endometrial cancer, genistein inhibits cell proliferation through different pathways, including decreased ER expression and the subsequent alteration of the AKT/Mammalian Target of Rapamycin (AKT/mTOR) and Mitogen-Activated Protein Kinase (MAPK) pathways [133, 134]. This evidence may support a promising therapeutic and preventive effect of genistein even in endometriosis, although the role in endometriosis therapy requires additional research.

Resveratrol

Resveratrol is polyphenol produced by many plants and associated with antioxidant, anti-inflammatory, and anti-angiogenic functions [135]. It was reported able to reduce lipid peroxidation, to increase antioxidant capacity, to downregulate pro-inflammatory cytokines, to induce apoptosis and to promote cell differentiation in endometriosis rat models [136, 137]. The proapoptotic functions were related to the activation of mitochondrial pathway inducing autophagy [138]. Its anti-angiogenic effect was related to the inhibition of VEGF gene and the modulation of matrix protein gene expression. Resveratrol suppressed inflammation through NF- κ B and MAPKs signaling pathways, downregulating ICAM1 expression and upregulating KLF2 expression [138]. Moreover, it significantly counteracts oxidative stress enhancing the expression of different antioxidant enzymes and was reported suppressing invasion, migration, and proliferation of carcinoma cells [139–141]. On that basis, this phenolic compound could be considered a new innovative drug in the prevention and treatment of this disease, although further studies are needed. Indeed, available data are still conflicting [142]. A randomized clinical trial by Mendes da Silva et al. compared resveratrol (40 mg/day) with the monophasic contraceptive pill (Combined Oral Contraceptive (COC)) to COC with placebo for the reduction of pain scores in women with a laparoscopic diagnosis of endometriosis. Forty-four women were randomized to receive COC (levonorgestrel 0.15 mg/ethinyl estradiol 0.03 mg) for 42 days to be taken with identical capsules containing 40 mg of resveratrol or placebo. Pain symptoms were evaluated using a visual analog scale. According to the

results of this study, resveratrol is not superior to placebo for the treatment of pain in endometriosis [143]. Conversely, the studies by Maia et al. resveratrol potentiates the effect of oral contraceptives in the management of endometriosis-associated dysmenorrhea since it further decreases aromatase and cyclooxygenase-2 expression in the endometrium [144].

***Pinus pinaster* bark**

Pinus pinaster bark is commonly used as nutrition, supplemental food, and herbal remedy. It is rich in polyphenols, especially taxifolin and catechin [56]. Several studies have confirmed the effectiveness of this plant with particular reference to anti-inflammatory effects, decrease in serum thromboxane concentration, relief of menstrual disorders and pregnancy-associated pain, and endometriosis, antimicrobial, and antiviral activities [145, 146].

It has been demonstrated that *P. pinaster* bark reduces symptoms without influencing menstrual cycles and estrogen levels in patients with endometriosis. Furthermore, it induces caspase-independent apoptosis [56].

Prunella vulgaris

Extracts of *Prunella vulgaris* (*Lamiaceae*) are currently used against HIV, herpes simplex virus, and allergic reactions, thanks to its antioxidative, antimicrobial and antiviral effects [56].

P. vulgaris is particularly rich in triterpenoids, flavonoids, tannins, oleanolic acid, betulinic acid, ursolic acid, polysaccharide prunelline, and rosmarinic acid [147].

P. vulgaris extract blocks the proliferation of ectopic endometrium and shows significant antiestrogenic properties [148]. Furthermore, it shows proapoptotic activity and decreases vascular inflammation through the suppression of the p38 ERK/MAPK signaling pathway and the inhibition of TNF- α -induced expression of intercellular adhesion molecules [149].

Inositol

The term inositol is commonly used to refer to a group of cyclic organic compounds belonging to the sugar family (molecular formula $C_6H_{12}O_6$) [150].

It is naturally found in cereals, corn, beans, and meat and is involved in several biological processes, among which endocrine function and reproduction [150, 151].

Myoinositol and D-chiroinositol (DCI) are the most known stereoisomers of inositol and the widest distributed in the human organism [150]. In recent years, several studies have investigated inositols as insulin-sensitizing integrative agents acting to, directly and indirectly, influence ovarian function. In this regard, it has been extensively reported that inositols have a key role in the treatment of infertility related to polycystic ovary syndrome, one of the commonest endocrine disorder among women of reproductive age [152–154].

Recently, the possible use of inositol (in particular, DCI) is also discussed to improve the fertility of patients suffering from endometriosis, thanks to its properties of oxidative stress reduction. Further studies are needed in order to better evaluate the potential efficacy and safety of DCI supplementation in balancing the oxidative status of patients suffering from endometriosis [155].

Conclusion

Based on the partial success of available interventions for the treatment of endometriosis, discovering new pharmaceutical agents seems to be necessary [3]. Phytotherapy, including medicinal plants, phytochemicals, and multicomponent herbal preparations, reported promising results from in vitro animal and human studies. In most of the medicinal plants, the effect on endometriosis can be attributed to phenolic compounds such as flavonoids and phenolic acids and their plant-derived secondary metabolites. These molecules reported the different mechanism of action including anti-inflammatory, antiproliferative, proapoptotic, antioxidant, antiangiogenesis, and immunomodulatory functions. Moreover, some investigated that phytochemical has been related to a strong phytoestrogenic effect modulating the estrogen activity.

Although available evidence suggests a utility of phytotherapy in endometriosis and provides the molecular mechanism explaining the results, the majority of studies had been performed in cellular and animal models

of endometriosis with a limited number of clinical studies [46, 50]. Therefore, the amount and quality of the available data are still insufficient to support a wide clinical application of phytotherapy for the management of endometriosis, and well-conducted clinical trials are mandatory to achieve more conclusive results about the role of phytotherapy in the management of endometriosis. However, because the treatment should be individually tailored to fit patients' needs, and a shared decision-making approach between patient and physician is greatly encouraged, available data may be enough to support phytotherapy as a potential and interesting addition to standard therapy schemes to provide a better control of endometriosis.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: None declared.

References

- [1] Parazzini F, Esposito G, Tozzi L, Noli S, Bianchi S. Epidemiology of endometriosis and its comorbidities. *Eur J Obstet Gynecol Reprod Biol* 2017;209:3–7.
- [2] Giudice LC. Clinical practice: endometriosis. *N Engl J Med* 2010;362:2389–98.
- [3] Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. *Nat Rev Dis Primer* 2018;4:9.
- [4] Maniglio P, Ricciardi E, Meli F, Vitale SG, Noventa M, Vitagliano A, et al. Catamenial pneumothorax caused by thoracic endometriosis. *Radiol Case Rep* 2018;13:81–5.
- [5] Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. *Fertil Steril* 2012;98:511–9.
- [6] Laganà AS, Vitale SG, Salmeri FM, Triolo O, Ban Frangež H, Vrtačnik-Bokal E, et al. Unus pro omnibus, omnes pro uno: a novel, evidence-based, unifying theory for the pathogenesis of endometriosis. *Med Hypotheses* 2017;103:10–20.
- [7] Laganà AS, Garzon S, Franchi M, Casarin J, Gullo G, Ghezzi F. Translational animal models for endometriosis research: a long and windy road. *Ann Transl Med* 2018;6:431.
- [8] Triolo O, Laganà AS, Sturlese E. Chronic pelvic pain in endometriosis: an overview. *J Clin Med Res* 2013;5:153–63.
- [9] Fauconnier A, Fritel X, Chapron C. [Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications]. *Gynecol Obstet Fertil* 2009;37:57–69.
- [10] Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications. *Hum Reprod Update* 2011;17:327–46.
- [11] Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. *Nat Rev Endocrinol* 2014;10:261–75.
- [12] Facchin F, Barbara G, Saita E, Mosconi P, Roberto A, Fedele L, et al. Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference. *J Psychosom Obstet Gynecol* 2015;36:135–41.
- [13] Laganà AS, La Rosa VL, Rapisarda AM, Valenti G, Sapia F, Chiofalo B, et al. Anxiety and depression in patients with endometriosis: impact and management challenges. *Int J Womens Health* 2017;9:323–30.
- [14] Vitale SG, La Rosa VL, Vitagliano A, Noventa M, Laganà FM, Ardizzone A, et al. Sexual function and quality of life in patients affected by deep infiltrating endometriosis: current evidence and future perspectives. *J Endometr Pelvic Pain Disord* 2017;9:270–4.
- [15] Vitale SG, La Rosa VL, Rapisarda AM, Laganà AS. Impact of endometriosis on quality of life and psychological well-being. *J Psychosom Obstet Gynaecol* 2017;38:317–9.
- [16] Pope CJ, Sharma V, Sharma S, Mazmanian D. A systematic review of the association between psychiatric disturbances and endometriosis. *J Obstet Gynaecol Can* 2015;37:1006–15.
- [17] Vitale SG, La Rosa VL, Rapisarda AM, Laganà AS. Endometriosis and infertility: the impact on quality of life and mental health. *J Endometr Pelvic Pain Disord* 2017;9:112–5.
- [18] Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. *Hum Reprod* 2014;29:400–12.
- [19] Hsu AL, Khachikyan I, Stratton P. Invasive and noninvasive methods for the diagnosis of endometriosis. *Clin Obstet Gynecol* 2010;53:413–9.
- [20] Buttice S, Laganà AS, Mucciardi G, Marson F, Tefik T, Netsch C, et al. Different patterns of pelvic ureteral endometriosis. What is the best treatment? Results of a retrospective analysis. *Arch Ital Urol Androl* 2016;88:266–9.
- [21] Heidemann LN, Hartwell D, Heidemann CH, Jochumsen KM. The relation between endometriosis and ovarian cancer - a review. *Acta Obstet Gynecol Scand* 2014;93:20–31.
- [22] Laganà AS, Sofo V, Vitale SG, Triolo O. Epithelial ovarian cancer inherent resistance: may the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role? *Gynecol Oncol Rep* 2016;18:57–8.
- [23] Aris A. Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie region of Quebec, Canada. *J Ovarian Res* 2010;3:2.

- [24] Bellia A, Vitale SG, Laganà AS, Cannone F, Houvenaeghel G, Rua S, et al. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: a retrospective, multicenter analysis. *Arch Gynecol Obstet* 2016;294:615–22.
- [25] Mogensen JB, Kjær SK, Mellemkjær L, Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. *Gynecol Oncol* 2016;143:87–92.
- [26] Vitale SG, Capriglione S, Zito G, Lopez S, Gulino FA, Di Guardo F, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. *Arch Gynecol Obstet* 2019;299:299–315.
- [27] Yu HC, Lin CY, Chang WC, Shen BJ, Chang WP, Chuang CM, et al. Increased association between endometriosis and endometrial cancer: a nationwide population-based retrospective cohort study. *Int J Gynecol Cancer* 2015;25:447–52.
- [28] Duffy JM, Arambage K, Correa FJ, Olive D, Farquhar C, Garry R, et al. Laparoscopic surgery for endometriosis. *Cochrane Database Syst Rev* 2014:CD011031. DOI: 10.1002/14651858.CD011031.pub2:CD011031.
- [29] Laganà AS, Vitale SG, Trovato MA, Palmara VI, Rapisarda AM, Granese R, et al. Full-thickness excision versus shaving by laparoscopy for intestinal deep infiltrating endometriosis: rationale and potential treatment options. *Biomed Res Int* 2016;2016:3617179.
- [30] Raffaelli R, Garzon S, Baggio S, Genna M, Pomini P, Laganà AS, et al. Mesenteric vascular and nerve sparing surgery in laparoscopic segmental intestinal resection for deep infiltrating endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2018;231:214–9.
- [31] Baggio S, Pomini P, Zecchin A, Garzon S, Bonin C, Santi L, et al. Delivery and pregnancy outcome in women with bowel resection for deep endometriosis: a retrospective cohort study. *Gynecol Surg* 2015;12:279–85.
- [32] Giampaolino P, Della Corte L, Saccone G, Vitagliano A, Bifulco G, Calagna G, et al. Role of ovarian suspension in preventing postsurgical ovarian adhesions in patients with stage III-IV pelvic endometriosis: a systematic review. *J Minim Invasive Gynecol* 2019;26:53–62.
- [33] Šalamun V, Verdenik I, Laganà AS, Vrtačnik-Bokal E. Should we consider integrated approach for endometriosis-associated infertility as gold standard management? Rationale and results from a large cohort analysis. *Arch Gynecol Obstet* 2018;297:613–21.
- [34] Avraham S, Seidman DS. Surgery versus pharmacological treatment for endometriosis. *Womens Health Lond Engl* 2014;10:161–6.
- [35] Sansone A, De Rosa N, Giampaolino P, Guida M, Laganà AS, Di Carlo C. Effects of etonogestrel implant on quality of life, sexual function, and pelvic pain in women suffering from endometriosis: results from a multicenter, prospective, observational study. *Arch Gynecol Obstet* 2018;298:731–6.
- [36] Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. *Obstet Gynecol* 2008;111:1285–92.
- [37] Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. *Hum Reprod* 2005;20:2698–704.
- [38] Bedaiwy MA, Alfaraaj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. *Fertil Steril* 2017;107:555–65.
- [39] Barra F, Grandi G, Tantari M, Scala C, Facchinetti F, Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. *Expert Opin Biol Ther* 2019;19:343–60.
- [40] Ferrero S, Barra F, Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. *Drugs* 2018;78:995–1012.
- [41] Brown J, Crawford TJ, Allen C, Hopewell S, Prentice A. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. *Cochrane Database Syst Rev* 2017;1:CD004753.
- [42] Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. *Fertil Steril* 2017;108:125–36.
- [43] Soares SR, Martínez-Varea A, Hidalgo-Mora JJ, Pellicer A. Pharmacologic therapies in endometriosis: a systematic review. *Fertil Steril* 2012;98:529–55.
- [44] Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. *J Assist Reprod Genet* 2010;27:441–7.
- [45] Ciebiera M, Łukaszyk K, Męczekalski B, Ciebiera M, Wojtyła C, Słabuszewska-Jóźwiak A, et al. Alternative oral agents in prophylaxis and therapy of uterine fibroids—an up-to-date review. *Int J Mol Sci* 2017;18:2586–604.
- [46] Armour M, Sinclair J, Chalmers KJ, Smith CA. Self-management strategies amongst Australian women with endometriosis: a national online survey. *BMC Complement Altern Med* 2019;19:1–8.
- [47] Fisher C, Sibbritt D, Hickman L, Adams J. A critical review of complementary and alternative medicine use by women with cyclic perimenstrual pain and discomfort: a focus upon prevalence, patterns and applications of use and users’ motivations, information seeking and self-perceived efficacy. *Acta Obstet Gynecol Scand* 2016;95:861–71.
- [48] Kong S, Zhang YH, Liu CF, Tsui I, Guo Y, Ai BB, et al. The complementary and alternative medicine for endometriosis: a review of utilization and mechanism. *Evid Based Complement Altern Med* 2014;2014:146383–99.
- [49] Schwartz AS, Gross E, Geraedts K, Rauchfuss M, Wölfler MM, Häberlin F, et al. The use of home remedies and complementary health approaches in endometriosis. *Reprod Biomed Online* 2019;38:260–71.
- [50] Mobli M, Qaraaty M, Amin G, Haririan I, Hajimahmoodi M, Rahimi R. Scientific evaluation of medicinal plants used for the treatment of abnormal uterine bleeding by Avicenna. *Arch Gynecol Obstet* 2015;292:21–35.
- [51] Mehriardestani M, Aliahmadi A, Toliat T, Rahimi R. Medicinal plants and their isolated compounds showing anti-Trichomonas vaginalis-activity. *Biomed Pharmacother Biomedecine Pharmacother* 2017;88:885–93.
- [52] Moore TR, Franks RB, Fox C. Review of efficacy of complementary and alternative medicine treatments for menopausal symptoms. *J Midwifery Womens Health* 2017;62:286–97.
- [53] Franco OH, Chowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. *JAMA* 2016;315:2554–63.
- [54] Rowland D, Tai W. A review of plant-derived and herbal approaches to the treatment of sexual dysfunctions. *J Sex Marital Ther* 2003;29:185–205.
- [55] Sofo V, Götte M, Laganà AS, Salmeri FM, Triolo O, Sturlese E, et al. Correlation between dioxin and endometriosis: an epigenetic route to unravel the pathogenesis of the disease. *Arch Gynecol Obstet* 2015;292:973–86.
- [56] Bina F, Soleymani S, Toliat T, Hajimahmoodi M, Tabarrai M, Abdollahi M, et al. Plant-derived medicines for treatment of endometriosis: a comprehensive review of molecular mechanisms. *Pharmacol Res* 2019;139:76–90.

- [57] Taniguchi F, Kaponis A, Izawa M, Kiyama T, Deura I, Ito M, et al. Apoptosis and endometriosis. *Front Biosci Elite Ed* 2011;3:648–62.
- [58] Sturlese E, Salmeri FM, Retto G, Pizzo A, De Dominicis R, Ardita FV, et al. Dysregulation of the Fas/FasL system in mononuclear cells recovered from peritoneal fluid of women with endometriosis. *J Reprod Immunol* 2011;92:74–81.
- [59] Vetvicka V, Laganà AS, Salmeri FM, Triolo O, Palmara VI, Vitale SG, et al. Regulation of apoptotic pathways during endometriosis: from the molecular basis to the future perspectives. *Arch Gynecol Obstet* 2016;294:897–904.
- [60] Takai E, Taniguchi F, Nakamura K, Uegaki T, Iwabe T, Harada T. Parthenolide reduces cell proliferation and prostaglandin E2 [corrected] in human endometriotic stromal cells and inhibits development of endometriosis in the murine model. *Fertil Steril* 2013;100:1170–8.
- [61] Klemmt PA, Starzinski-Powitz A. Molecular and cellular pathogenesis of endometriosis. *Curr Womens Health Rev* 2018;14:106–16.
- [62] Riccio LD, Santulli P, Marcellin L, Abrão MS, Batteux F, Chapron C. Immunology of endometriosis. *Best Pract Res Clin Obstet Gynaecol* 2018;50:39–49.
- [63] Salmeri FM, Laganà AS, Sofo V, Triolo O, Sturlese E, Retto G, et al. Behavior of tumor necrosis factor- α and tumor necrosis factor receptor 1/tumor necrosis factor receptor 2 system in mononuclear cells recovered from peritoneal fluid of women with endometriosis at different stages. *Reprod Sci* 2015;22:165–72.
- [64] Laganà AS, Triolo O, Salmeri FM, Granese R, Palmara VI, Ban Frangež H, et al. Natural Killer T cell subsets in eutopic and ectopic endometrium: a fresh look to a busy corner. *Arch Gynecol Obstet* 2016;293:941–9.
- [65] Scutiero G, Iannone P, Bernardi G, Bonaccorsi G, Spadaro S, Volta CA, et al. Oxidative stress and endometriosis: a systematic review of the literature. *Oxid Med Cell Longev* 2017;2017:7265238.
- [66] Vitale SG, Capriglione S, Peterlunger I, La Rosa VL, Vitagliano A, Noventa M, et al. The role of oxidative stress and membrane transport systems during endometriosis: a fresh look at a busy corner. *Oxid Med Cell Longev* 2018;2018:7924021.
- [67] Bałkowiec M, Maksym RB, Włodarski PK. The bimodal role of matrix metalloproteinases and their inhibitors in etiology and pathogenesis of endometriosis (Review). *Mol Med Rep* 2018;18:3123–36.
- [68] Starzinski-Powitz A, Handrow-Metzmacher H, Kotzian S. The putative role of cell adhesion molecules in endometriosis: can we learn from tumour metastasis? *Mol Med Today* 1999;5:304–9.
- [69] Liu Y, Sun L, Hou Z, Mao Y, Cui Y, Liu J. rhTNFR: Fc suppresses the development of endometriosis in a mouse model by downregulating cell proliferation and invasiveness. *Reprod Sci* 2016;23:847–57.
- [70] Laganà AS, Salmeri FM, Vitale SG, Triolo O, Götte M. Stem cell trafficking during endometriosis: may epigenetics play a pivotal role? *Reprod Sci* 2018;25:978–9.
- [71] Stephens L, Whitehouse J, Polley M. Western herbal medicine, epigenetics, and endometriosis. *J Altern Complement Med N Y N* 2013;19:853–9.
- [72] Shrivastava R, John GW. Treatment of Aphthous Stomatitis with topical *Alchemilla vulgaris* in glycerine. *Clin Drug Investig* 2006;26:567–73.
- [73] Stanilova M, Gorgorov R, Trendafilova A, Nikolova M, Vitkova A. Influence of nutrient medium composition on in vitro growth, polyphenolic content and antioxidant activity of *Alchemilla mollis*. *Nat Prod Commun* 2012;7:761–6.
- [74] Küpeli Akkol E, Demirel MA, Bahadır Acikara O, Süntar I, Ergene B, İlhan M, et al. Phytochemical analyses and effects of *Alchemilla mollis* (Buser) Rothm. and *Alchemilla persica* Rothm. in rat endometriosis model. *Arch Gynecol Obstet* 2015;292:619–28.
- [75] Shrivastava R, Cucuat N, John GW. Effects of *Alchemilla vulgaris* and glycerine on epithelial and myofibroblast cell growth and cutaneous lesion healing in rats. *Phytother Res* 2007;21:369–73.
- [76] Kim KH, Park JK, Choi YW, Kim YH, Lee EN, Lee JR, et al. Hexane extract of aged black garlic reduces cell proliferation and attenuates the expression of ICAM-1 and VCAM-1 in TNF- α -activated human endometrial stromal cells. *Int J Mol Med* 2013;32:67–78.
- [77] Bayan L, Koulivand PH, Gorji A. Garlic: a review of potential therapeutic effects. *Avicenna J Phytomedicine* 2014;4:1–14.
- [78] Xiao D, Li M, Herman-Antosiewicz A, Antosiewicz J, Xiao H, Lew KL, et al. Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGFR2. *Nutr Cancer* 2006;55:94–107.
- [79] Xu Y, Feng J, Zhang D, Zhang B, Luo M, Su D, et al. S-allylcysteine, a garlic derivative, suppresses proliferation and induces apoptosis in human ovarian cancer cells in vitro. *Acta Pharmacol Sin* 2014;35:267–74.
- [80] Hodge G, Hodge S, Han P. *Allium sativum* (garlic) suppresses leukocyte inflammatory cytokine production in vitro: potential therapeutic use in the treatment of inflammatory bowel disease. *Cytometry* 2002;48:209–15.
- [81] Padiya R, Chowdhury D, Borkar R, Srinivas R, Pal Bhadra M, Banerjee SK. Garlic attenuates cardiac oxidative stress via activation of PI3K/AKT/Nrf2-Keap1 pathway in fructose-fed diabetic rat. *PLoS One* 2014;9:e94228.
- [82] Avci A, Atli T, Ergüder IB, Varlı M, Devrim E, Aras S, et al. Effects of garlic consumption on plasma and erythrocyte antioxidant parameters in elderly subjects. *Gerontology* 2008;54:173–6.
- [83] Pittler MH, Ernst E. Clinical effectiveness of garlic (*Allium sativum*). *Mol Nutr Food Res* 2007;51:1382–5.
- [84] Farhadi F, Jahanpour S, Hazem K, Aghbali A, Baradaran B, Vahid Pakdel SM. Garlic (*Allium sativum*) fresh juice induces apoptosis in human oral squamous cell carcinoma: the involvement of Caspase-3, Bax and Bcl-2. *J Dent Res Dent Clin Dent Prospects* 2015;9:267–73.
- [85] Tu Q, Wang R, Ding B, Zhong W, Cao H. Protective and antioxidant effect of Danshen polysaccharides on cerebral ischemia/reperfusion injury in rats. *Int J Biol Macromol* 2013;60:268–71.
- [86] Qian Q, Qian S, Fan P, Huo D, Wang S. Effect of *Salvia miltiorrhiza* hydrophilic extract on antioxidant enzymes in diabetic patients with chronic heart disease: a randomized controlled trial. *Phytother Res PTR* 2012;26:60–6.
- [87] Su CY, Ming QL, Rahman K, Han T, Qin LP. *Salvia miltiorrhiza*: Traditional medicinal uses, chemistry, and pharmacology. *Chin J Nat Med* 2015;13:163–82.
- [88] Hung YC, Pan TL, Hu WL. Roles of reactive oxygen species in anticancer therapy with *Salvia miltiorrhiza* Bunge. *Oxid Med Cell Longev* 2016;2016:5293284.
- [89] Cao Y, Huang B, Gao C. *Salvia miltiorrhiza* extract dihydrotanshinone induces apoptosis and inhibits proliferation of glioma cells. *Bosn J Basic Med Sci* 2017;17:235–40.
- [90] Liu JJ, Lin DJ, Liu PQ, Huang M, Li XD, Huang RW. Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro. *J Biomed Sci* 2006;13:813–23.

- [91] Xing Y, Tu J, Zheng L, Guo L, Xi T. Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells. *Oncol Rep* 2015;33:163–70.
- [92] Tsai MY, Yang RC, Wu HT, Pang JH, Huang ST. Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells. *Cancer Lett* 2011;310:198–206.
- [93] Kim JM, Noh EM, Song HK, Lee M, Lee SH, Park SH, et al. Salvia miltiorrhiza extract inhibits TPA-induced MMP-9 expression and invasion through the MAPK/AP-1 signaling pathway in human breast cancer MCF-7 cells. *Oncol Lett* 2017;14:3594–600.
- [94] Nizamutdinova IT, Lee GW, Lee JS, Cho MK, Son KH, Jeon SJ, et al. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. *Carcinogenesis* 2008;29:1885–92.
- [95] Zhou ZH, Weng Q, Zhou JH, Zhou J. Extracts of Salvia miltiorrhiza Bunge on the cytokines of rat endometriosis models. *Afr J Tradit Complement Altern Med* 2012;9:303–14.
- [96] Moon S, Shin S, Kim S, Oh HE, Han S, Lee S, et al. Role of Salvia miltiorrhiza for modulation of Th2-derived Cytokines in the resolution of inflammation. *Immune Netw* 2011;11:288–98.
- [97] Ma S, Zhang D, Lou H, Sun L, Ji J. Evaluation of the anti-inflammatory activities of tanshinones isolated from Salvia miltiorrhiza var. alba roots in THP-1 macrophages. *J Ethnopharmacol* 2016;188:193–9.
- [98] Han JM, Kim MJ, Baek SH, An S, Jin YY, Chung HG, et al. Antiatherosclerotic effects of Artemisia princeps Pampanini cv. Sajabal in LDL receptor deficient mice. *J Agric Food Chem* 2009;57:1267–74.
- [99] Chen CC, Lin MW, Liang CJ, Wang SH. The anti-inflammatory effects and mechanisms of eupafolin in lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. *PLoS One* 2016;11:e0158662.
- [100] Kim MJ, Han JM, Jin YY, Baek NI, Bang MH, Chung HG, et al. In vitro antioxidant and anti-inflammatory activities of Jaceosidin from Artemisia princeps Pampanini cv. Sajabal. *Arch Pharm Res* 2008;31:429–37.
- [101] Chang SH, Jung EJ, Park YH, Lim DG, Ko NY, Choi WS, et al. Anti-inflammatory effects of Artemisia princeps in antigen-stimulated T cells and regulatory T cells. *J Pharm Pharmacol* 2009;61:1043–50.
- [102] Kim JH, Jung SH, Yang YI, Ahn JH, Cho JG, Lee KT, et al. Artemisia leaf extract induces apoptosis in human endometriotic cells through regulation of the p38 and NF- κ B pathways. *J Ethnopharmacol* 2013;145:767–75.
- [103] Salehi B, Albayrak S, Antolak H, Kręgiel D, Pawlikowska E, Sharifi-Rad M, et al. Aloe genus plants: from farm to food applications and phytopharmacotherapy. *Int J Mol Sci* 2018;19:2843–92.
- [104] Radha MH, Laxmipriya NP. Evaluation of biological properties and clinical effectiveness of Aloe vera: a systematic review. *J Tradit Complement Med* 2015;5:21–6.
- [105] Budai MM, Varga A, Milesz S, Tózsér J, Benkő S. Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages. *Mol Immunol* 2013;56:471–9.
- [106] López A, de Tangil MS, Vega-Orellana O, Ramírez AS, Rico M. Phenolic constituents, antioxidant and preliminary antimycoplasmic activities of leaf skin and flowers of Aloe vera (L.) Burm. f. (syn. A. barbadensis Mill.) from the Canary Islands (Spain). *Mol Basel Switz* 2013;18:4942–54.
- [107] Bostanci MS, Bakacak M, Kizilkale Yildirim O, Yildirim G, Attar R, Özkan F, et al. Effects of aloe vera gel on the induction of endometriosis and regression of endometrial explants in a rat model. *Clin Exp Obstet Gynecol* 2016;43:529–33.
- [108] Yilmaztekin M, Sislioglu K. Changes in volatile compounds and some physicochemical properties of european cranberrybush (*Viburnum opulus* L.) during ripening through traditional fermentation. *J Food Sci* 2015;80:C687–94.
- [109] Saltan C, Süntar I, Ozbilgin S, İlhan M, Demirel MA, Oz BE, et al. *Viburnum opulus* L.: A remedy for the treatment of endometriosis demonstrated by rat model of surgically-induced endometriosis. *J Ethnopharmacol* 2016;193:450–5.
- [110] İlhan M, Süntar İ, Demirel MA, Yeşilada E, Keleş H, Küpeli Akkol E. A mixture of St. John's wort and sea buckthorn oils regresses endometriotic implants and affects the levels of inflammatory mediators in peritoneal fluid of the rat: a surgically induced endometriosis model. *Taiwan J Obstet Gynecol* 2016;55:786–90.
- [111] Cai L, Shu Y, Xie H. [Clinical and experimental study on the treatment of endometriosis with dan'e mixture]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 1999;19:159–61.
- [112] Sun X, Chen L, Zeng F. Effects of Chinese materia Medica-Fubao Danggui Jiao on experimental endometriosis. *Afr J Tradit Complement Altern Med* 2011;8:224–9.
- [113] Jiao L, Qi X, Lu G, Zhang Q, Zhang C, Gao J. Effect of traditional Chinese medicine (Xiaochaihu Tang) on the expression of MMP-2 and MMP-9 in rats with endometriosis. *Exp Ther Med* 2013;6:1385–9.
- [114] Hewlings SJ, Kalman DS. Curcumin: a review of its' effects on human health. *Foods* 2017;6:92–103.
- [115] Haghi A, Azimi H, Rahimi R. A comprehensive review on pharmacotherapeutics of three phytochemicals, curcumin, quercetin, and allicin, in the treatment of gastric cancer. *J Gastrointest Cancer* 2017;48:314–20.
- [116] Kocaadam B, Şanlıer N. Curcumin, an active component of turmeric (*Curcuma longa*), and its effects on health. *Crit Rev Food Sci Nutr* 2017;57:2889–95.
- [117] Zhang Y, Cao H, Yu Z, Peng HY, Zhang CJ. Curcumin inhibits endometriosis endometrial cells by reducing estradiol production. *Iran J Reprod Med* 2013;11:415–22.
- [118] Xu S, Yang Z, Fan Y, Guan B, Jia J, Gao Y, et al. Curcumin enhances temsirolimus-induced apoptosis in human renal carcinoma cells through upregulation of YAP/p53. *Oncol Lett* 2016;12:4999–5006.
- [119] Yu Z, Shah DM. Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells. *Gynecol Oncol* 2007;106:541–8.
- [120] Yoosungnoen B, Bhattarakosol P, Patumraj S, Changtam C. Effects of tetrahydrocurcumin on hypoxia-inducible factor-1 α and vascular endothelial growth factor expression in cervical cancer cell-induced angiogenesis in nude mice. *Biomed Res Int* 2015;2015:391748.
- [121] Cao WG, Morin M, Metz C, Maheux R, Akoum A. Stimulation of macrophage migration inhibitory factor expression in endometrial stromal cells by interleukin 1, beta involving the nuclear transcription factor NF κ B. *Biol Reprod* 2005;73:565–70.
- [122] Kumari A, Dash D, Singh R. Curcumin inhibits lipopolysaccharide (LPS)-induced endotoxemia and airway inflammation through modulation of sequential release of inflammatory mediators (TNF- α and TGF- β 1) in murine model. *Inflammopharmacology* 2017;25:329–41.

- [123] Ali BH, Al-Salam S, Al Suleimani Y, Al Kalbani J, Al Bahlani S, Ashique M, et al. Curcumin ameliorates kidney function and oxidative stress in experimental chronic kidney disease. *Basic Clin Pharmacol Toxicol* 2018;122:65–73.
- [124] Lee AY, Fan CC, Chen YA, Cheng CW, Sung YJ, Hsu CP, et al. Curcumin inhibits invasiveness and epithelial-mesenchymal transition in oral squamous cell carcinoma through reducing matrix metalloproteinase 2, 9 and modulating p53-E-Cadherin pathway. *Integr Cancer Ther* 2015;14:484–90.
- [125] Arablou T, Kolahdouz-Mohammadi R. Curcumin and endometriosis: review on potential roles and molecular mechanisms. *Biomed Pharmacother Biomedecine Pharmacother* 2018;97:91–7.
- [126] Farzaei MH, Bahramsoltani R, Rahimi R. Phytochemicals as adjunctive with conventional anticancer therapies. *Curr Pharm Des* 2016;22:4201–18.
- [127] Cui S, Wang J, Wu Q, Qian J, Yang C, Bo P. Genistein inhibits the growth and regulates the migration and invasion abilities of melanoma cells via the FAK/paxillin and MAPK pathways. *Oncotarget* 2017. DOI: 10.18632/oncotarget.15535.
- [128] Yavuz E, Oktem M, Esinler I, Toru SA, Zeyneloglu HB. Genistein causes regression of endometriotic implants in the rat model. *Fertil Steril* 2007;88:1129–34.
- [129] Wei D, Yang L, Lv B, Chen L. Genistein suppresses retinoblastoma cell viability and growth and induces apoptosis by upregulating miR-145 and inhibiting its target ABCE1. *Mol Vis* 2017;23:385–94.
- [130] Yu X, Zhu J, Mi M, Chen W, Pan Q, Wei M. Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. *Med Oncol Northwood Lond Engl* 2012;29:349–57.
- [131] Geng Y, Zhu S, Cheng P, Lu ZM, Xu HY, Shi JS, et al. Bioassay-guided fractionation of ethyl acetate extract from *Armillaria mellea* attenuates inflammatory response in lipopolysaccharide (LPS) stimulated BV-2 microglia. *Phytomedicine Int J Phytother Phytopharm* 2017;26:55–61.
- [132] Surico D, Ercoli A, Farruggio S, Raina G, Filippini D, Mary D, et al. Modulation of oxidative stress by 17 β -Estradiol and genistein in human hepatic cell lines in vitro. *Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol* 2017;42:1051–62.
- [133] Sutrisno S, Aprina H, Simanungkalit HM, Andriyani A, Barlianto W, Sujuti H, et al. Genistein modulates the estrogen receptor and suppresses angiogenesis and inflammation in the murine model of peritoneal endometriosis. *J Tradit Complement Med* 2018;8:278–81.
- [134] Malloy KM, Wang J, Clark LH, Fang Z, Sun W, Yin Y, et al. Novasoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways. *Am J Transl Res* 2018;10:784–95.
- [135] Farzaei MH, Rahimi R, Nikfar S, Abdollahi M. Effect of resveratrol on cognitive and memory performance and mood: a meta-analysis of 225 patients. *Pharmacol Res* 2018;128:338–44.
- [136] Yavuz S, Aydin NE, Celik O, Yilmaz E, Ozerol E, Tanbek K. Resveratrol successfully treats experimental endometriosis through modulation of oxidative stress and lipid peroxidation. *J Cancer Res Ther* 2014;10:324–9.
- [137] Bayoglu Tekin Y, Guven S, Kirbas A, Kalkan Y, Tumkaya L, Guvendag Guven ES. Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis? *Eur J Obstet Gynecol Reprod Biol* 2015;184:1–6.
- [138] Chu H, Li H, Guan X, Yan H, Zhang X, Cui X, et al. Resveratrol protects late endothelial progenitor cells from TNF- α -induced inflammatory damage by upregulating Krüppel-like factor-2. *Mol Med Rep* 2018;17:5708–15.
- [139] Truong VL, Jun M, Jeong WS. Role of resveratrol in regulation of cellular defense systems against oxidative stress. *BioFactors Oxf Engl* 2018;44:36–49.
- [140] Zhao Y, Tang H, Zeng X, Ye D, Liu J. Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal cell carcinoma cells. *Biomed Pharmacother Biomedecine Pharmacother* 2018;98:36–44.
- [141] Dull AM, Moga MA, Dimienescu OG, Sechel G, Burteta V, Anastasiu CV. Therapeutic approaches of resveratrol on endometriosis via anti-inflammatory and anti-angiogenic pathways. *Molecules* 2019;24:667.
- [142] Barra F, Scala C, Mais V, Guerriero S, Ferrero S. Investigational drugs for the treatment of endometriosis, an update on recent developments. *Expert Opin Investig Drugs* 2018;27:445–58.
- [143] Mendes Da Silva D, Gross LA, Neto EP, Lessey BA, Savaris RF. The use of resveratrol as an adjuvant treatment of pain in endometriosis: a randomized clinical trial. *J Endocr Soc* 2017;1:359–69.
- [144] Maia H Jr., Haddad C, Pinheiro N, Casoy J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. *Int J Womens Health* 2012;4:543–9.
- [145] Iravani S, Zolfaghari B. Pharmaceutical and nutraceutical effects of *Pinus pinaster* bark extract. *Res Pharm Sci* 2011;6:1–11.
- [146] Iravani S, Zolfaghari B. Phytochemical analysis of *Pinus eldarica* bark. *Res Pharm Sci* 2014;9:243–50.
- [147] Psoťová J, Kolár M, Soušek J, Svagera Z, Vicar J, Ulrichová J. Biological activities of *Prunella vulgaris* extract. *Phytother Res* 2003;17:1082–7.
- [148] Collins NH, Lessey EC, DuSell CD, McDonnell DP, Fowler L, Palomino WA, et al. Characterization of antiestrogenic activity of the Chinese herb, *Prunella vulgaris*, using in vitro and in vivo (Mouse Xenograft) models. *Biol Reprod* 2009;80:375–83.
- [149] Park SH, Koo HJ, Sung YY, Kim HK. The protective effect of *Prunella vulgaris* ethanol extract against vascular inflammation in TNF- α -stimulated human aortic smooth muscle cells. *BMB Rep* 2013;46:352–7.
- [150] Clements RS Jr., Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. *Am J Clin Nutr* 1980;33:1954–67.
- [151] Schlemmer U, Frölich W, Prieto RM, Grases F. Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. *Mol Nutr Food Res* 2009;53:S330–75.
- [152] Reyes-Muñoz E, Sathyapalan T, Rossetti P, Shah M, Long M, Buscema M, et al. Polycystic ovary syndrome: implication for drug metabolism on assisted reproductive techniques—a literature review. *Adv Ther* 2018;35:1805–15.
- [153] Laganà AS, Rossetti P, Sapia F, Chiofalo B, Buscema M, Valenti G, et al. Evidence-based and patient-oriented inositol treatment in polycystic ovary syndrome: changing the perspective of the disease. *Int J Endocrinol Metab* 2017;15:e43695.
- [154] Vitale SC, Rossetti P, Corrado F, Rapisarda AM, La Vignera S, Condorelli RA, et al. How to achieve high-quality oocytes? The key role of myo-inositol and melatonin. *Int J Endocrinol* 2016;2016:4987436.

- [155] Vitagliano A, Noventa M, Gizzo S. Is it time to consider patients suffering from endometriosis-related infertility as “novel candidates” for targeted peri-conceptional D-chiro inositol supplementation? Hypothesis, rationale and some considerations.] *Assist Reprod Genet* 2015;32:407–8.